Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579816 | 0.92 | GSK3A (0.49) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL3062340 | 0.76 | GSK3A (0.62) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL30479909 | 0.76 | MAPT (0.49) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL9470544 | 0.75 | KEAP1 (0.48) | KDM1AHTR1ADRD2HTR6KEAP1 | |
| SCHEMBL186221 | 0.72 | MEN1 (0.62) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL11022809 | 0.72 | MEN1 (0.57) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL14850663 | 0.71 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL28886326 | 0.71 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL16274020 | 0.71 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A | |
| SCHEMBL20176213 | 0.71 | MEN1 (0.65) | MEN1KMT2AGAAALDH1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | disclosed |
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2008-02-14 | — | — | US | disclosed |
| EP-1846383-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | Insight Biopharmaceuticals Ltd. (IL) | 2007-10-24 | — | — | EP | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | MEN1 3009/4885KMT2A 3403/4885GAA 1550/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | MEN1 2216/4885KMT2A 1040/4885GAA 1739/4885 |
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | HPSE, HEXA, GAA | MEN1 3219/4885KMT2A 1428/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.